Skip to main content
Scientific publications

At Day One, we use the power of leading-edge science to improve patient outcomes.

We believe timely and transparent dissemination of data from our clinical trials and other studies is essential to inform clinical decision making and to advance scientific understanding. Our comprehensive list of publications is below.
September 2024
Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory (R/R) Melanoma or Other Solid Tumors with RAF Fusions and/or RAF1 Amplification.
Vieito M, Garralda Cabanas E, Mehmi I, Gaudy-Marqueste C, O’Neil BH, Medina TM, Body Arance A, Kummar S, Najjar YG, Bedard PL, Chu C, McKenna C, Hume S, Kopp LM, Lee J.
614MO - Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory (R/R) Melanoma or Other Solid Tumors with RAF Fusions and/or RAF1 Amplification. Mini oral presentation at: ESMO Congress 2024; September 14, 2024; Barcelona, Spain.
June 2024
Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial.
Kline C, Waanders AJ, Ziegler DS, Kilburn LB, Nysom K, van der Lugt J, Hassall TE, Gerber NU, Segal D, Larouche V, Khuong-Quang D-A, Hansford JR, Leary SES, Hernáiz Driever P, Bailey S, Perreault S, McCowage G, Witt O, Baxter PA, Kang HJ, Han JW, Hargrave D, Franson AT, Yalon Oren M, Toledano H, Abdelbaki MS, Jabado N, Gottardo NG, Whipple NS, Chi, Oren L, Tan EEK, Mueller S, Wright KD, Blackman SC, Qiu J, Podesta D, Walter A, Da Costa D, Manley P, McLeod L, Landi DB.
LGG-40. Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial. Oral presentation at: 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024); June 30, 2024; Philadelphia, PA.
June 2024
Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial
Kline C, Waanders AJ, Ziegler DS, Kilburn LB, Nysom K, van der Lugt J, Hassall TE, Gerber NU, Segal D, Larouche V, Mueller S, Walter A, Manley P, McLeod L, Landi DB.
Abstract 10036. Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial. Poster presentation at: 2024 ASCO (American Society for Clinical Oncology) Annual Meeting; June 1, 2024; Chicago, IL & Virtual.
April 2024
Disease burden and healthcare utilization in pediatric low-grade glioma: a United States retrospective study of linked claims and electronic health records
Zelt S, Cooney T, Yu S, Daral S, Krebs B, Markan R, Manley P, Kieran M, Govinda Raju S.
Disease burden and healthcare utilization in pediatric low-grade glioma: a United States retrospective study of linked claims and electronic health records [published online ahead of print April 27, 2024]. Neuro-Oncol Pract. 2024.
April 2024
Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or a NF1-LOF mutation
Rastogi S, Perino S, Lal-Nag M, Wang Y, Blackman SC, Venetsanakos E.
1972. Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or a NF1-LOF mutation. Poster presentation at: AACR (American Association for Cancer Research) Annual Meeting 2024; April 8, 2023; San Diego, CA.
April 2024
Clinical activity and safety of tovorafenib in patients with optic pathway gliomas in FIREFLY-1
Leary SES, de Vos-Kerkhof E, Perreault S, Witt O, Ziegler DS, Hernáiz Driever P, Franson AT, Baxter PA, Whipple NS, Kline C, Segal D, Jabado N, Bailey S, McCowage G, Hansford JR, Khuong-Quang D-A, Gottardo HG, Hassall T, Han JW, Yalon Oren M, Chi SN, McLeod L, Qiu J, McKenna C, Da Costa D, Govinda Raju S, Hargrave D, Kilburn LB, Landi DB, Nysom K.
902. Clinical Activity and Safety of Tovorafenib in Patients with Optic Pathway Gliomas in FIREFLY-1. Poster presentation at: 2024 ASPHO (American Society of Pediatric Hematology/Oncology); April 4 & 5, 2024; Seattle, WA.